CONCLUSION

The combination of ipilimumab and nivolumab is approved in front-line intermediate and poor risk mRCC on the basis of improved OS compared to sunitinib. The benefits of this combination is also noted in sub-populations such as those who have brain metastases, favorable risk profile, and non-clear cell histology. Although a multitude of questions remain unanswered, ongoing clinical trials will serve to guide the use of ipilimumab and nivolumab and refine its application across mRCC patients.

Disclosure


Continue Reading

Moshe C. Ornstein reports grant support from Pfizer, BMS; speaking: BMS, Exelixis; education support: Pfizer; consulting: BMS, Pfizer, Exelixis. The authors report no other conflicts of interest in this work.


Iris Y. Sheng, Moshe C. Ornstein

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Center Institute, Cleveland, OH, USA

Correspondence: Moshe C Ornstein Tel +1 216-445-6592
Fax +1 216-444-9464
Email [email protected]


References

1. Key Statistics About Kidney Cancer. Available from: https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Accessed December 24, 2019.

2. Kidney Cancer – Statistics. Cancer.Net. [updated June 25, 2012]. Available from: https://www.cancer.net/cancer-types/kidney-cancer/statistics. Accessed December 24, 2019.

3. Cancer of the kidney and renal pelvis – cancer stat facts. SEER. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed December 24, 2019.

4. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–696. doi:10.1200/JCO.1995.13.3.688

5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55–57.

6. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high – dose and low – dose inter leukin – 2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–3132. doi:10.1200/JCO.2003.02.122

7. McDermott DF, Cheng S-C, Signoretti S, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(3):561–568. doi:10.1158/1078-0432.CCR-14-1520

8. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239

9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690

10. Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019; e192187. doi:10.1001/jamaoncol.2019.2187.

11. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–1437. doi:10.1200/JCO.2014.59.0703

12. McDermott DF, Motzer RJ, Atkins MB, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. JCO. 2016;34(15_suppl):4507. doi:10.1200/JCO.2016.34.15_suppl.4507

13. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665

14. Motzer RJ, Tykodi SS, Escudier B, et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). JCO. 2020;38(6_suppl):617. doi:10.1200/JCO.2020.38.6_suppl.617

15. Vitale MG, Scagliarini S, Galli L, et al. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab expanded access program (EAP) in Italy. PLoS One. 2018;13(7):e0199642. doi:10.1371/journal.pone.0199642

16. Laurence Albiges SN, Ci le Dalban CC, Medical Oncology GR, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study. ASCO Meeting library. February 2019. Available from: https://meetinglibrary.asco.org/record/170207/abstract. Accessed February 28, 2019.

17. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (Anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–830. doi:10.1097/CJI.0b013e318156e47e

18. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836

19. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:10.1056/NEJMoa1302369

20. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. JCO. 2017;35(34):3851–3858. doi:10.1200/JCO.2016.72.1985

21. Hammers H, Plimack ER, Infante JR, et al. Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): the CheckMate 016 study. Ann Oncol. 2016;27(suppl_6):vi364. doi:10.1093/annonc/mdw378.16

22. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126

23. Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019;20(2):297–310. doi:10.1016/S1470-2045(18)30778-2

24. Tannir NM, McDermott DF, Escudier B, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). JCO. 2020;38(6_suppl):609. doi:10.1200/JCO.2020.38.6_suppl.609

25. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology. 2017;19(11):1511–1521. doi:10.1093/neuonc/nox077

26. Flippot R, Dalban C, Laguerre B, et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol. 2019;37(23):2008–2016. doi:10.1200/JCO.18.02218

27. Emamekhoo H, Olsen M, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: interim analysis of CheckMate 920. JCO. 2019;37(15_suppl):4517. doi:10.1200/JCO.2019.37.15_suppl.4517

28. Dizman N Clinical activity of ipilimumab plus nivolumab in patients with metastatic non–clear cell RCC. Practice update. [updated December 23, 2019]. Available from: https://www.practiceupdate.com/content/clinical-activity-of-ipilimumab-plus-nivolumab-in-patients-with-metastatic-non-clear-cell-rcc/93720. Accessed December 26, 2019.

29. McKay RR, Bossé D, Xie W, et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 2018;6(7):758–765. doi:10.1158/2326-6066.CIR-17-0475

30. Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0319-9

31. Chahoud J, Campbell MT, Gao J, et al. Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institution experience. JCO. 2018;36(15_suppl):4585. doi:10.1200/JCO.2018.36.15_suppl.4585

32. Gupta R, Ornstein MC, Li H, et al. Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma – ScienceDirect. Clin Genitourin Cancer. 2019. doi:10.1016/j.clgc.2019.11.012

33. Randomized phase-II study of nivolumab plus ipilimumab vs. standard of care in untreated and advanced non-clear cell RCC – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03075423. Accessed January 19, 2020.

34. Phase II sequential treatment trial of single agent nivolumab, then combination ipilimumab + nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma (ANZUP1602) – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03177239. Accessed January 20, 2020.

35. Pichler M, Hutterer G, Chromecki T, et al. External validation of the leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine PubMed NCBI. J Urol. 2011;186(5):1773–1777. doi:10.1016/j.juro.2011.07.034

36. Bakouny Z, Vokes N, Gao X, et al. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). JCO. 2019;37(15_suppl):4514. doi:10.1200/JCO.2019.37.15_suppl.4514

37. Leroy X, Zini L, Buob D, Ballereau C, Villers A, Aubert S. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med. 2007;131(1):102–106. doi:10.1043/1543-2165(2007)131[102:RCCWRF]2.0.CO;2

38. McDermott DF, Choueiri TK, Motzer RJ, et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. JCO. 2019;37(15_suppl):4513. doi:10.1200/JCO.2019.37.15_suppl.4513

39. Samiei A, Tayshetye P, Sanguino A, et al. The clinical outcome of renal cell carcinoma with rhabdoid and sarcomatoid differentiation. JCO. 2019;37(15_suppl):e16083. doi:10.1200/JCO.2019.37.15_suppl.e16083

40. Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC): journal of clinical oncology: vol 36, no 6_suppl. J Clin Oncol. 2018;36(6):578. doi:10.1200/JCO.2018.36.6_suppl.578

41. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. JCO. 2019;37(15_suppl):4500. doi:10.1200/JCO.2019.37.15_suppl.4500

42. Rini BI, Motzer RJ, Powles T, et al. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: iMmotion151 subgroup analysis. JCO. 2019;37(15_suppl):4512. doi:10.1200/JCO.2019.37.15_suppl.4512

43. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714

44. Wynja E, Solomon B, Bleeker J. Complete and prolonged response of renal cell carcinoma with rhabdoid features to checkpoint inhibitor therapy. PubMed NCBI. J Immunother. 2018;41(7):340–342. doi:10.1097/CJI.0000000000000238

45. Immunotherapy with nivolumab and ipilimumab followed by nivolumab or nivolumab with cabozantinib for patients with advanced kidney cancer, the PDIGREE study – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03793166. Accessed January 20, 2020.

46. Testing the effectiveness of two immunotherapy drugs (nivolumab and ipilimumab) with one anti-cancer targeted drug (cabozantinib) for rare genitourinary tumors – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03866382. Accessed April 20, 2020.

47. Zimmer L, Apuri S, Eroglu Z, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47–55. doi:10.1016/j.ejca.2017.01.009

48. Gul A, Shah NJ, Mantia C, et al. Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC). JCO. 2019;37(7_suppl):669. doi:10.1200/JCO.2019.37.7_suppl.669

49. Nivolumab in combination with ipilimumab in patients with metastatic renal cell carcinoma – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03297593. Accessed January 20, 2020.

50. Study of optimized management of nivolumab based on response in patients with advanced RCC (OMNIVORE study) – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03203473. Accessed January 19, 2020.

51. Study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03117309. Accessed January 19, 2020.

52. Rini BI, McDermott DF, Hammers H, et al. Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4(1):81. doi:10.1186/s40425-016-0180-7

53. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–1251. doi:10.1016/S1470-2045(19)30388-2

54. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385. doi:10.1016/S1470-2045(19)30413-9

55. Ornstein MC, Wood LS, Hobbs BP, et al. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. J Immunother Cancer. 2019;7(1):127. doi:10.1186/s40425-019-0615-z

56. Intermittent therapy in metastatic renal cell carcinoma patients treated with ipilimumab and nivolumab – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03126331. Accessed January 20, 2020.

57. Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J ImmunoTher Cancer. 2019;7(1):341. doi:10.1186/s40425-019-0779-6

58. Trinh S, Le A, Gowani S, La-Beck NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac J Oncol Nurs. 2019;6(2):154–160. doi:10.4103/apjon.apjon_3_19

59. Common terminology criteria for adverse events (CTCAE) | protocol development | CTEP. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed July 30, 2019.

60. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. JCO. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385

61. NCCN. Management of immunotherapy- related toxicity. Available from: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed January 19, 2020.

62. A study to evaluate the safety of nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell cancer – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02982954. Accessed January 20, 2020.

63. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–376. doi:10.1093/annonc/mdw443

64. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–240. doi:10.1001/jamaoncol.2015.4368

65. Wang DY, Salem J-E, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923

66. Trial of SBRT in combination with nivolumab/ipilimumab in RCC/kidney cancer patients – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03065179. Accessed January 20, 2020.

67. Study of entinostat with nivolumab plus ipilimumab in previously treated renal cell carcinoma – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03552380. Accessed January 20, 2020.

68. Study of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma – full text view – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03937219. Accessed January 20, 2020.

Source: Cancer Management and Research.
Originally published June 23, 2020.

READ FULL ARTICLE Curated publisher From Dovepress